A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

HPV Infection Clinical Trial

Official title:

A Randomised, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 18-45 Years

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06454175
• Other study ID #: 15-HPV-1001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: July 5, 2024
• Est. completion date: July 5, 2025

Study information

• Verified date: June 2024
• Source: Shanghai Bovax Biotechnology Co., Ltd.
• Contact: LIRONG HUANG, Master
• Phone: 13978620932
• Email: hlr620[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.

Description:

A phase 1 random, double blind, placebo control trail was plan to conducted in 72 healthy participants in the 2 age groups(18-45 years old and 9-17 years old). The 72 subjects to be inoculated with middle and high dose vaccine first in sequence if there was no safety issue.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: July 5, 2025
• Est. primary completion date: February 5, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 9 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Participants aged 9-45;

2. Participans aged 18-45 who can provide legal identification,participants aged 9-17 and their guardian can provide legal identification;

3. Participants and/or their guardian sign an informed consent form (a 9-17 year old participant signs an informed notification);

4. Axillary temperature was less than 37.3 ?(>14 years old)or less than 37.5?(=14 years old)at the time of enrollment;

5. Be able to comply with study protocol requirements;

6. Women were not pregnant at the time of enrollment (negative blood pregnancy test), did not have lactation period,had no birth plan within the 30 days after receiving the whole vaccination;

7. Women with reproductive age take effective contraceptive measures within 2 weeks before enrollment in the study;

8. Agree to take effective contraceptive measures within 30 days after receiving the whole vaccination (effective contraceptives include: oral contraceptives, injection or embedding contraceptives, sustained release topical contraceptives, hormone patches, intrauterine devices), sterilization, abstinence, condoms (male), diaphragms, cervical caps, etc.

9. Women who receiving hormone test has a regular menstruation for more than one year

Exclusion Criteria:

1. Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period;

2. Plan to participate other clinical trials during the study period,or participated other clinical trials within 3 months before enrollment, including vaccine or drug;

3. Before the first dose is vaccinated, the laboratory test indicators specified in the program are abnormal, except for NCS determined by the clinician;

4. History of CIN2/AIS/Cervical Cancer/Pelvic radiation therapy;

5. History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis/perianal/perineum intraepithelial neoplasia, Penile/perianal/perineal cancer) ?anal intraepithelial neoplasia and related cancer, or head and neck cancer;history of sexually transmitted diseases (including syphilis, Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);

6. Has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosu, rheumatoid arthritis, juvenile Rheumatoid arthritis, Pernicious Anemia, Ulcerative colitis or other autoimmune conditions (such as Type 1 diabetes, Graves' disease, hashimoto thyroiditi, etc.);

7. History of convulsions, epilepsy, except of febrile convulsions in children 5 years of age and younger;

8. History of severe allergy that requires medical intervention, including but not limited to severe adverse reactions caused by vaccine or drug, eg anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia sexual purpura, local allergic necrosis (Arthus reaction), widespread urticaria, dyspnea, angioedema, etc.; History of severe side effect caused by vaccination or severe allergy to any of the components of the investigational vaccine, including histidine, sodium chloride, aluminium phosphate, Polysorbate 80 and water for injection;

9. Suffering from severe cardiovascular disease, severe liver and kidney disease, malignant tumor, and serious infectious disease, such as: tuberculosis, viral hepatitis, etc.;

10. Before the enrollment, the physical examination was untreatment or uncontrolled hypertension, (18-45 year olds: systolic blood pressure =140mmHg and / or diastolic blood pressure =90mmHg, 9-17 year olds: systolic blood pressure =120mmHg and / or diastolic blood pressure =80mmHg);

11. Coagulation disorders: such as Congenital or acquired hemophilia, Coagulation factor deficiency, clotting disorders, thrombocytopenia, etc.;

12. No spleen or functional spleen, and no spleen caused by any condition;

13. Receive any Immunosuppressive therapy product within 1 month prior to the first vaccination, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination),e.g. systemic medication for glucocorticoid (>20mg/day or 2mg/kg/day, continuous use =2 weeks), but local medication can be used (such as ointment, eye drops, inhalants) Or nasal spray);

14. Receive any immunoglobulin or blood product within 3 months prior to the first injection, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination);

15. 3 days before vaccination, suffering from acute illness or acute exacerbation of chronic disease; using fever reducer, Antihistamines, and Analgesics(such as: Acetaminophen, Ibuprofen, Aspirin, loratadine, Cetirizine, etc. )

16. Receiving inactivated vaccine or recombinant vaccine or live-attenuated vaccine or nucleic acid vaccine or adenovirus vaccine within 14 days before vaccination;

17. History of mental disorders or family history of mental health disorder (immediate family)

18. Plan to move out of the city before the end of the study or leave the local area for a long time during the scheduled study visit;

19. The investigator believes that the participant has any condition that may interfere with the assessment of the purpose of the study.

Related Conditions & MeSH terms

• Condylomata Acuminata
• Genital Wart
• HPV Infection
• HPV-Related Carcinoma
• Papillomavirus Infections

Intervention

Biological:
• Placebo
immunization schedule:Month 0,Month 2,Month 6
• 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
immunization schedule:Month 0,Month 2,Month 6

Locations

Country	Name	City	State
China	Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention	Guangxi

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Bovax Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Adverse Events	AE of local and systemic reactions within 30 minutes after each dose	Up to 30 minutes after any vaccination
Primary	Percentage of Participants With Solicited Adverse Events	The percentage of participants with one or more solicited AEs was assessed.	Up to 14 days after any vaccination
Primary	Percentage of Participants With Unsolicited Adverse Events	The percentage of participants with one or more unsolicited AEs was assessed.	Up to 30 days after any vaccination
Primary	Percentage of Participants With Serious Adverse Events	The percentage of participants with one or more SAEs was assessed	From Day 0 after the first dose of vaccination to 6 months after the thrid dose
Primary	Percentage of Female Participants With Pregnancy Events	The percentage of participants with Pregnancy Events was assessed	From Day 0 after the first dose of vaccination to 6 months after the thrid dose